Profile data is unavailable for this security.
About the company
Amplifon SpA is an Italy-based company active in the hearing care retail market. The Company provides personalized solutions and customer care to hearing-impaired people. It offers a wide range of services from diagnosing hearing difficulties, to fitting, servicing and maintaining hearing aids. The Company is organized in three geographical operating segments: Europe, Middle East and Africa - EMEA - (Italy, France, The Netherlands, Germany, the United Kingdom, Ireland, Spain, Portugal, Switzerland, Belgium, Luxemburg, Hungary, Egypt, Turkey, Poland and Israel), Americas (USA, Canada, Chile, Argentina, Ecuador, Colombia, Panama and Mexico) and Asia-Pacific (Australia, New Zealand, India and China).
- Revenue in EUR (TTM)2.32bn
- Net income in EUR161.58m
- Incorporated--
- Employees14.38k
- LocationAmplifon SpAVia Ripamonti 133MILANO 20141ItalyITA
- Phone+39 2574721
- Fax+39 257300033
- Websitehttps://www.amplifon.com/
Mergers & acquisitions
Acquired company | AMP:MIL since announced | Transaction value |
---|---|---|
Miracle-Ear Centers of Arkansas LLC | -12.35% | -- |
Las Davis Enterprises Inc | -12.35% | -- |
Hearing Pro Inc | -12.35% | -- |
Audical SRL | -12.73% | -- |
Living Sounds Hearing Centre | -8.99% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ambu A/S | 705.54m | 60.33m | 4.05bn | 4.82k | 75.94 | 5.95 | 36.58 | 5.73 | 1.69 | 1.69 | 19.80 | 21.60 | 0.7459 | 2.18 | 7.17 | 1,140,165.00 | 6.38 | 3.81 | 7.37 | 4.62 | 58.88 | 59.37 | 8.55 | 5.43 | 1.51 | 74.38 | 0.0961 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
Getinge AB | 2.90bn | 145.90m | 4.24bn | 11.85k | 31.16 | 1.74 | 13.37 | 1.46 | 6.21 | 6.21 | 123.33 | 111.09 | 0.5937 | 2.51 | 7.30 | 2,861,487.00 | 3.01 | 5.31 | 4.00 | 6.98 | 45.80 | 47.83 | 5.07 | 8.69 | 0.5965 | 10.34 | 0.2629 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
Sectra AB | 156.18m | 38.59m | 4.48bn | 1.22k | 123.95 | 33.50 | 94.86 | 28.66 | 2.31 | 2.31 | 9.36 | 8.55 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
SCHOTT Pharma AG & Co KgaA | 948.56m | 150.41m | 4.54bn | 4.65k | 30.08 | 5.91 | 21.43 | 4.78 | 1.00 | 1.00 | 6.31 | 5.10 | 0.7434 | 4.34 | 4.07 | 204,166.20 | 11.82 | -- | 16.42 | -- | 34.18 | -- | 15.90 | -- | 1.06 | -- | 0.1086 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
ConvaTec Group PLC | 2.03bn | 141.13m | 5.36bn | 10.13k | 38.07 | 3.51 | 15.65 | 2.64 | 0.0575 | 0.0575 | 0.8258 | 0.6229 | 0.5965 | 2.47 | 5.89 | 167,589.00 | 4.15 | 2.36 | 4.74 | 2.73 | 55.96 | 55.03 | 6.96 | 4.34 | 1.27 | 2.96 | 0.4604 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
Carl Zeiss Meditec AG | 2.07bn | 203.20m | 5.42bn | 4.95k | 26.58 | -- | -- | 2.62 | 2.28 | 2.28 | 23.14 | -- | -- | -- | -- | 428,397.90 | -- | 9.56 | -- | 11.72 | 55.12 | 57.84 | 9.84 | 13.15 | -- | -- | -- | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
Ypsomed Holding AG | 582.88m | 83.28m | 5.61bn | 2.30k | 67.32 | 8.54 | 34.41 | 9.62 | 5.74 | 5.74 | 40.18 | 45.26 | 0.5587 | 5.40 | 4.96 | 238,875.00 | 7.98 | 4.41 | 12.40 | 6.81 | 34.47 | 27.26 | 14.29 | 7.38 | 0.5967 | 20.89 | 0.293 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
DiaSorin SpA | 1.16bn | 167.74m | 5.67bn | 3.19k | 33.66 | 3.35 | 18.68 | 4.89 | 3.01 | 3.01 | 21.78 | 30.31 | 0.3668 | 1.26 | 6.09 | 359,117.20 | 5.28 | 10.30 | 5.78 | 11.50 | 64.81 | 66.70 | 14.40 | 21.25 | 1.89 | 12.28 | 0.3892 | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
Amplifon SpA | 2.32bn | 161.58m | 5.87bn | 14.38k | 36.28 | 5.16 | 13.23 | 2.53 | 0.7153 | 0.7153 | 10.27 | 5.03 | 0.6229 | 21.46 | 10.96 | 161,594.30 | 4.33 | 4.31 | 6.53 | 5.81 | 24.56 | 59.01 | 6.95 | 7.28 | 0.3992 | 6.12 | 0.5921 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
Demant A/S | 3.00bn | 354.98m | 7.63bn | 21.50k | 21.48 | 5.94 | -- | 2.54 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
Holder | Shares | % Held |
---|---|---|
Comgest SAas of 28 Jun 2024 | 5.23m | 2.31% |
The Vanguard Group, Inc.as of 02 Oct 2024 | 4.46m | 1.97% |
Allianz Global Investors GmbHas of 30 Aug 2024 | 2.85m | 1.26% |
Cr�dit Mutuel Asset Management SAas of 28 Mar 2024 | 2.42m | 1.07% |
T. Rowe Price International Ltd.as of 30 Sep 2024 | 2.37m | 1.05% |
BlackRock Fund Advisorsas of 03 Oct 2024 | 2.35m | 1.04% |
Amundi Asset Management SA (Investment Management)as of 02 Oct 2024 | 2.19m | 0.97% |
Norges Bank Investment Managementas of 02 May 2024 | 2.06m | 0.91% |
DNCA Finance SAas of 31 Dec 2023 | 1.67m | 0.74% |
Mirova SA (Investment Management)as of 31 May 2024 | 1.57m | 0.70% |